Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus

Annals of Internal Medicine

Volumn 135, Issue 9, 2001, Pages 759-768

  McMahon, B J ^a   Holck, P ^a   Bulkow, L ^a   Snowball, M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CHILD; DISEASE CARRIER; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MASS SCREENING; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SEROLOGY; UNITED STATES;

EID: 0035818616     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-135-9-200111060-00006     Document Type: Article

References (40)

1. Hepatitis B virus infection
2. Hepatocellular carcinoma and viral hepatitis
3. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis
4. Natural history of liver disease in chronic hepatitis B surface antigen carriers. Survey of 100 patients from Great Britain
5. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis
6. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B
7. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection
8. Incidence, determinants and significance of delayed dearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study
9. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
10. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state
11. Epidemiology of hepatitis B in two Alaska communities
12. Prevalence of hepatitis B in selected Alaskan Eskimo villages
13. A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives
14. Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives
15. Early detection of primary hepatocellular carcinoma. Screening for primary, hepatocellular carcinoma among persons infected with hepatitis B virus
16. Survival in chronic hepatitis B. An analysis of 379 patients
17. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
18. Survival and prognostic indicators in hepatitis B surface antigenpositive cirrhosis of the liver
19. The hepatitis B carrier state-A follow-up study of 100 consecutive cases
20. Hepatitis B virus. The major etiology of hepatocellular carcinoma
21. Increased risk for lethal forms of liver disease among HBsAg -positive blood donors in the United States
22. Mortality of hepatitis B-positive blood donors in England and Wales
23. Hepatocellular carcinoma among female Japanese hepatitis B virus carriers
24. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population
25. The natural history of asymptomatic hepatitis B surface antigen carriers
26. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)
27. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
28. Spontaneous reactivation of chronic hepatitis B virus infection
29. Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody-positive patients
30. Long-term remission of chronic hepatitis B after alpha-interferon therapy
31. Clearance of HBsAg in seven patients with chronic hepatitis B
32. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis
33. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen
34. Hepatitis B virions isolated with antibodies to the pre-S1 domain reveal occult viremia by PCR in Alaska Native HBV carriers who have seroconverted
35. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: With special emphasis on the clearance of hepatitis B e antigen before 3 years of age
36. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: Implications for interferon therapy
37. Regional prevalence of hepatitis B, delta, and human immunodeficiency virus infection in southern Africa: A large population survey
38. A prospective study of hepatitis B virus serologic markers and liver enzymes
39. A one-year trial of lamivudine for chronic hepatitis B
40. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection